Sanja Dacic, MD, PhD
Professor of PathologyCards
About
Research
Publications
2026
237P NeoADAURA: Positron emission tomography response criteria in solid tumors (PERCIST) outcomes following neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CTx) vs placebo (PBO) + CTx in patients (pts) with (w) resectable, EGFRm stage II–IIIB NSCLC
Hochmair M, Tsuboi M, Blakely C, Weder W, Spicer J, He J, Dacic S, Chen K, Park S, Lee K, Hoang G, Darapureddi R, Robichaux J, Huang X, Dayal A, Chaft J. 237P NeoADAURA: Positron emission tomography response criteria in solid tumors (PERCIST) outcomes following neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CTx) vs placebo (PBO) + CTx in patients (pts) with (w) resectable, EGFRm stage II–IIIB NSCLC. ESMO Open 2026, 11: 106545. DOI: 10.1016/j.esmoop.2026.106545.Peer-Reviewed Original Research1597 Comparative Clinicopathologic and Survival Analysis of Lung Adenocarcinoma, LCNEC, and NSCLC with Neuroendocrine Features
Amraei R, Ragoowansi H, Walther Z, Kahila M, Woodard G, Dacic S. 1597 Comparative Clinicopathologic and Survival Analysis of Lung Adenocarcinoma, LCNEC, and NSCLC with Neuroendocrine Features. Laboratory Investigation 2026, 106: 105899. DOI: 10.1016/j.labinv.2025.105899.Peer-Reviewed Original ResearchMolecular Pathology of Lung Cancer
Lingard A, Dacic S. Molecular Pathology of Lung Cancer. Surgical Pathology Clinics 2026 DOI: 10.1016/j.path.2026.01.003.Peer-Reviewed Original Research
2025
MET alterations are enriched in lung adenocarcinoma brain metastases, defining a distinct biologic subtype
Burns T, Dacic S, Chakka A, Miller E, Velez M, Somasundaram A, Bhattacharya S, Gaither-Davis A, Devadassan P, Jin J, Kumar V, Pennathur A, Xiu J, Oberley M, Glantz M, Aulakh S, Chandran U, Bao R, Tatsuoka C, Stabile L. MET alterations are enriched in lung adenocarcinoma brain metastases, defining a distinct biologic subtype. Journal Of Clinical Investigation 2025, 136: e194708. PMID: 41411048, PMCID: PMC12904726, DOI: 10.1172/jci194708.Peer-Reviewed Original ResearchNon-small cell lung cancerBrain metastasesMET amplificationLung adenocarcinomaMET alterationsEvidence of metabolic adaptationRate of brain metastasesPrimary lung adenocarcinomaCirculating tumor DNACell lung cancerEpithelial-mesenchymal transition signalingExpression of Twist1Extracranial metastasesBM patientsInhibitors in vivoOverall survivalBiological subtypesTumor DNATumor microenvironmentLung adenocarcinoma brain metastasisSolid tumorsNon-smallLung cancerClinical challengeMetastasisOA02.02 Molecular Residual Disease (MRD) Analysis from NeoADAURA: Neoadjuvant Osimertinib ± Chemotherapy in Resectable EGFRm NSCLC
Blakely C, Robichaux J, Lee S, Shih J, Lee K, Nhung N, Saeteng S, Chaft J, He J, Weder W, Dacic S, Yatabe Y, Escriu C, Tsuboi M, Bhetariya P, Swaminathan B, Rukazenkov Y, Hartmaier R, Hochmair M. OA02.02 Molecular Residual Disease (MRD) Analysis from NeoADAURA: Neoadjuvant Osimertinib ± Chemotherapy in Resectable EGFRm NSCLC. Journal Of Thoracic Oncology 2025, 20: s12-s13. DOI: 10.1016/j.jtho.2025.09.032.Peer-Reviewed Original ResearchNeoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in resectable (R) epidermal growth factor receptor-mutated (EGFRm) NSCLC: NeoADAURA.
Chaft J, Weder W, He J, Chen K, Hochmair M, Shih J, Lee S, Lee K, Nhung N, Saeteng S, Teixeira C, Escriu C, Martinez-Marti A, Blakely C, Yatabe Y, Dacic S, Huang X, Rukazenkov Y, Dayal A, Tsuboi M. Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in resectable (R) epidermal growth factor receptor-mutated (EGFRm) NSCLC: NeoADAURA. Journal Of Clinical Oncology 2025, 43: 8001-8001. DOI: 10.1200/jco.2025.43.16_suppl.8001.Peer-Reviewed Original ResearchEvent-free survivalPathological complete responseMPR rateStatistically significant improvementPathologic complete response rateEvent-free survival rateEvent-free survival dataCentral pathology reviewLong-term outcomesComplete responseEGFR-TKIsPathology reviewComplete surgeryEligible ptsRandomized 1:1:1Secondary endpointsCT armBaseline characteristicsPathological responseSignificant improvementChemotherapyEGFRmPlaceboFollow-upHazard ratioRandomized Phase II Clinical Trial of Sulforaphane in Former Smokers at High Risk for Lung Cancer.
Yuan J, Kensler T, Dacic S, Hartman D, Wang R, Balogh P, Sufka P, Turner M, Fuhrer K, Seigh L, Pham Y, Adams-Haduch J, Valacchi G, Singh S, Herman J, Wilson D. Randomized Phase II Clinical Trial of Sulforaphane in Former Smokers at High Risk for Lung Cancer. Cancer Prevention Research 2025, 18: 335-345. PMID: 40041932, DOI: 10.1158/1940-6207.capr-24-0386.Peer-Reviewed Original ResearchConceptsKi-67 indexRandomized phase II clinical trialKi-67TUNEL indexBronchial biopsiesSulforaphane groupCaspase-3Lung cancerFormer smokersOral supplementationClinical trialsNo severe AEsProliferative marker Ki-67Surrogate endpointsIntake of cruciferous vegetablesAssociated with lower incidenceApoptotic marker caspase-3Severe adverse eventsBioavailability of sulforaphaneRandomized clinical trialsLung cancer developmentLung cancer riskHigher bioavailabilityDaily doseAdverse eventsComparative performance of PD‐L1 scoring by pathologists and AI algorithms
Plass M, Olteanu G, Dacic S, Kern I, Zacharias M, Popper H, Fukuoka J, Ishijima S, Kargl M, Murauer C, Kalson L, Brcic L. Comparative performance of PD‐L1 scoring by pathologists and AI algorithms. Histopathology 2025, 87: 90-100. PMID: 39961605, PMCID: PMC12129605, DOI: 10.1111/his.15432.Peer-Reviewed Original ResearchConceptsTumor proportion scoreNon-small cell lung carcinomaTumor proportion score cutoffPD-L1 expressionPD-L1Interobserver agreementImmune-checkpoint inhibitorsPD-L1 scoringCell lung carcinomaNon-small cell lung carcinoma treatmentModerate interobserver agreementNSCLC casesPredictive biomarkersLung carcinomaTherapeutic responseProportion scoreComparative effectivenessInterobserver concordancePathologist scoresWhole-slide imagesIntraobserver consistencyCohen's kappaPathologistsVisiopharmScores
2024
Sex-based differences in CEACAM5 expression in lung cancer
Woodard G, Kane E, Todorovic N, Prince S, Dacic S, Chen L. Sex-based differences in CEACAM5 expression in lung cancer. Translational Cancer Research 2024, 13: 6394-6402. PMID: 39697744, PMCID: PMC11651760, DOI: 10.21037/tcr-24-983.Peer-Reviewed Original ResearchMA08.12 Semi-Sold Lung Nodule Growth Rates, Need for Treatment, and Cancer-Specific Verses All-Cause Mortality in a Large North American Population
Woodard G, Kane E, Prince S, Blasberg J, Dhanasopon A, Boffa D, Mase V, Dacic S, Bader A, Detterbeck F. MA08.12 Semi-Sold Lung Nodule Growth Rates, Need for Treatment, and Cancer-Specific Verses All-Cause Mortality in a Large North American Population. Journal Of Thoracic Oncology 2024, 19: s87. DOI: 10.1016/j.jtho.2024.09.156.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
News
News
- March 24, 2026
AI in Cancer Workshop: Advancing Precision Medicine through Interdisciplinary Innovation
- March 17, 2026
Yale Pathology Will Have Strong Presence at USCAP 2026
- September 08, 2025Source: OncoDaily
Dr. Sanja Dacic Awarded the 2025 Mary J. Matthews Pathology/Translational Research Award
- July 07, 2025
International Exchange Fosters Clinical and Research Collaboration
Get In Touch
Contacts
Email
Locations
Yale New Haven Hospital
Academic Office
20 York Street, Rm EP2-631
New Haven, CT 06510